The effect of maintenance macrolide antibiotic de-escalation during the Australian summer season on exacerbations of respiratory diseases such as asthma, COPD and bronchiectasis

Not Applicable

• Conditions: Asthma; Chronic obstructive pulmonary disease; Non-cystic fibrosis bronchiectasis; Respiratory - Asthma; Respiratory - Chronic obstructive pulmonary disease; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12620001263987
• Lead Sponsor: Hunter New England Local Health District

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-11-24
• Last Update Posted: 30 November 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

At least 18 years of age; currently receiving maintenance macrolide therapy (azithromycin, clarithromycin, roxithromycin or erythromycin) for the management of obstructive airway disease (asthma, COPD or bronchiectasis) for a period of at least 6 months; able to provide verbal informed consent; have access to a telephone; and willing to complete baseline and follow-up telephone interviews.

Exclusion Criteria

Pregnant women (self-reported); patients with cystic fibrosis; the use of a macrolide for other conditions (e.g, mycobacterium avium complex infection, MAC) and unable to speak and understand English.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Exacerbation rate in summer (proportions of patients experiencing at least one exacerbation during the Australian summer season will be assessed and compared between groups). The self-reported exacerbations will be assessed at each follow-up interview using a study-specific questionnaire. [Three months after starting the study treatment. The three-month follow-up will be conducted at the end of the summer season to evaluate the exacerbation rate in summer. ]

Secondary Outcome Measures

Name	Time	Method
Self-reported number of hospitalisations at each follow-up[3-month, 6-month and 9-month ];Self-reported number of emergency department visit at each follow-up [3-month, 6-month and 9-month];Self-reported use of corticosteroid and antibiotics at each follow-up [3-month, 6-month and 9-month]